The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Development of TLR9 agonists for cancer therapy
Open accessAbstract
In vertebrates, the TLRs are a family of specialized immune receptors that induce protective immune responses when they detect highly conserved pathogen-expressed molecules.Synthetic agonists for several TLRs, including TLR3, TLR4, TLR7, TLR8, and TLR9, have been or are being developed for the treatment of cancer.TLR9 detects the unmethylated CpG dinucleotides prevalent in bacterial and viral DNA but not in vertebrate genomes.As discussed in this Review, short synthetic oligodeoxynucleotides containing these immune stimulatory CpG motifs activate TLR9 in vitro and in vivo, inducing innate and adaptive immunity, and are currently being tested in multiple phase II and phase III human clinical trials as adjuvants to cancer vaccines and in combination with conventional chemotherapy and other therapies.Nonstandard abbreviations used: CpG ODN, oligodeoxynucleotide(s) containing one or more unmethylated CpG dinucleotides; HBsAg, HBV surface antigen; IFA, incomplete Freund's adjuvant; KLH, keyhole limpet hemocyanin; MART1, melanoma-associated antigen recognized by T cells 1; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung carcinoma; ODN, oligodeoxynucleotide; pDC, plasmacytoid DC; PS, phosphorothioate; PS ODN, ODN that have a nuclease-resistant phosphorothioate backbone.Conflict of interest: A.M. Krieg is a founder and employee of and shareholder in Coley Pharmaceutical Group and has a financial interest in the development of TLR9 agonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 2×
“TLR9 seems to be required for all the immune stimulatory responses to synthetic PS ODN, since there is a complete loss of activity in mice genetically deficient for TLR9 (6, 8, 9).”
BackgroundTakeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors
Liu, Y.-J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115633 · Cited by 1,625
TLR9 signals after translocating from the ER to CpG DNA in the lysosome
Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K. A., Monks, B. G., Knetter, C. F., Lien, E., Nilsen, N. J., Espevik, T., & Golenbock, D. T. (2004) · Nature Immunology · doi:10.1038/ni1028 · Cited by 1,361
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Self-citationMouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022
Recognition of Cytosolic DNA Activates an IRF3-Dependent Innate Immune Response
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2005.12.003 · Cited by 1,008
CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., & Harding, C. V. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1623 · Cited by 1,002
Self-citationImmunostimulatory DNA sequences function as T helper-1-promoting adjuvants
Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M.-D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., & Raz, E. (1997) · Nature Medicine · doi:10.1038/nm0897-849 · Cited by 908
Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
A Toll-like receptor–independent antiviral response induced by double-stranded B-form DNA
Ishii, K. J., Coban, C., Kato, H., Takahashi, K., Torii, Y., Takeshita, F., Ludwig, H., Sutter, G., Suzuki, K., Hemmi, H., et al. (2006) · Nature Immunology · doi:10.1038/ni1282 · Cited by 775
TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity
Creagh, E. M., & O’Neill, L. A. J. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.06.003 · Cited by 762
Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C.-C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 760
Toll-like receptor 2 controls expansion and function of regulatory T cells
Sutmuller, R. P. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25439 · Cited by 756
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523373 · Cited by 640
Self-citationMoseman, E. A., Liang, X., Dawson, A. J., Panoskaltsis-Mortari, A., Krieg, A. M., Liu, Y.-J., Blazar, B. R., & Chen, W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4433 · Cited by 637
Self-citationTranslating Innate Immunity into Immunological Memory: Implications for Vaccine Development
Pulendran, B., & Ahmed, R. (2006) · Cell · doi:10.1016/j.cell.2006.02.019 · Cited by 625
Boonstra, A., Asselin-Paturel, C., Gilliet, M., Crain, C., Trinchieri, G., Liu, Y.-J., & O'Garra, A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021908 · Cited by 551
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Toll‐like receptor 9 binds single‐stranded CpG‐DNA in a sequence‐ and pH‐dependent manner
Rutz, M., Metzger, J., Gellert, T., Luppa, P., Lipford, G. B., Wagner, H., & Bauer, S. (2004) · European Journal of Immunology · doi:10.1002/eji.200425218 · Cited by 503
Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P. A., Thomas, R. K., von Bergwelt-Baildon, M., Debey, S., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0642 · Cited by 492
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 453
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 417
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J.-P. H., Bieler, J. G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042167 · Cited by 399
Lipford, G. B., Bauer, M., Blank, C., Reiter, R., Wagner, H., & Heeg, K. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270931 · Cited by 383
Fonteneau, J.-F., Gilliet, M., Larsson, M., Dasilva, I., Münz, C., Liu, Y.-J., & Bhardwaj, N. (2003) · Blood · doi:10.1182/blood-2002-10-3063 · Cited by 346
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Hemmi, H., Kaisho, T., Takeda, K., & Akira, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3059 · Cited by 340
COOPER, C. L., DAVIS, H. L., MORRIS, M. L., EFLER, S. M., ADHAMI, M. A., KRIEG, A. M., CAMERON, D. W., & HEATHCOTE, J. (2004) · Journal of Clinical Immunology · doi:10.1007/s10875-004-6244-3 · Cited by 330
Self-citationMellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., & Munn, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5601 · Cited by 290
Okabe, Y., Kawane, K., Akira, S., Taniguchi, T., & Nagata, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051654 · Cited by 275
Halperin, S. A., Van Nest, G., Smith, B., Abtahi, S., Whiley, H., & Eiden, J. J. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00045-8 · Cited by 259
Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D., & Persing, D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1129 · Cited by 256
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Krieg, A. M., Li, Y., Laframboise, C., Al Adhami, M. J., Khaliq, Y., Seguin, I., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.01.058 · Cited by 248
Self-citationHigh Accumulation of T Regulatory Cells Prevents the Activation of Immune Responses in Aged Animals
Sharma, S., Dominguez, A. L., & Lustgarten, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8348 · Cited by 239
Oldenhove, G., de Heusch, M., Urbain-Vansanten, G., Urbain, J., Maliszewski, C., Leo, O., & Moser, M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030654 · Cited by 225
Innate immune recognition of, and regulation by, DNA
ISHII, K., & AKIRA, S. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.09.002 · Cited by 224
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1
Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000475 · Cited by 212
Pashenkov, M., Goëss, G., Wagner, C., Hörmann, M., Jandl, T., Moser, A., Britten, C. M., Smolle, J., Koller, S., Mauch, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9129 · Cited by 210
Self-citationUpon TLR9 Signaling, CD5+ B Cells Control the IL-12-Dependent Th1-Priming Capacity of Neonatal DCs
Sun, C.-M., Deriaud, E., Leclerc, C., & Lo-Man, R. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.008 · Cited by 204
Franzius, C., Daldrup-Link, H. E., Wagner-Bohn, A., Sciuk, J., Heindel, W. L., Jürgens, H., & Schober, O. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf012 · Cited by 203
Wooldridge, J. E., Ballas, Z., Krieg, A. M., & Weiner, G. J. (1997) · Blood · doi:10.1182/blood.v89.8.2994 · Cited by 203
Self-citationKubo, T., Hatton, R. D., Oliver, J., Liu, X., Elson, C. O., & Weaver, C. T. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7249 · Cited by 201
Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines
Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Ménard, C., Ghiringhelli, F., Terme, M., Carpentier, A. F., Darrasse-Jèse, G., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2722 · Cited by 200
Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides
Krieg, A. M. (2004) · Current Oncology Reports · doi:10.1007/s11912-004-0019-0 · Cited by 200
Self-citationSpies, B., Hochrein, H., Vabulas, M., Huster, K., Busch, D. H., Schmitz, F., Heit, A., & Wagner, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5908 · Cited by 199
Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer
Sfondrini, L., Rossini, A., Besusso, D., Merlo, A., Tagliabue, E., Mènard, S., & Balsari, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6624 · Cited by 194
Cooper, C. L., Davis, H. L., Angel, J. B., Morris, M. L., Elfer, S. M., Seguin, I., Krieg, A. M., & Cameron, D. W. (2005) · AIDS · doi:10.1097/01.aids.0000183514.37513.d2 · Cited by 191
Self-citationWhitmore, M. M., DeVeer, M. J., Edling, A., Oates, R. K., Simons, B., Lindner, D., & Williams, B. R. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0063 · Cited by 183
Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy
Emens, L. A., & Jaffee, E. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1797 · Cited by 182
Dávila, E., Kennedy, R. B., & Celis, E. (2003) · PubMed · Cited by 182
den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Toonen, L. W. J., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0206 · Cited by 176
Role of Toll‐like receptors in costimulating cytotoxic T cell responses
Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A. M., Sirard, J., Röthlisberger, P., & Bachmann, M. F. (2003) · European Journal of Immunology · doi:10.1002/eji.200323919 · Cited by 171
Correale, P., Cusi, M. G., Tsang, K. Y., Del Vecchio, M. T., Marsili, S., Placa, M. L., Intrivici, C., Aquino, A., Micheli, L., Nencini, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.147 · Cited by 171
Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO
Wingender, G., Garbi, N., Schumak, B., Jüngerkes, F., Endl, E., von Bubnoff, D., Steitz, J., Striegler, J., Moldenhauer, G., Tüting, T., et al. (2006) · European Journal of Immunology · doi:10.1002/eji.200535602 · Cited by 170
Variegation of the Immune Response with Dendritic Cells and Pathogen Recognition Receptors
Pulendran, B. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2457 · Cited by 169
Romero, P., Valmori, D., Pittet, M. J., Zippelius, A., Rimoldi, D., Lévy, F., Dutoit, V., Ayyoub, M., Rubio‐Godoy, V., Michielin, O., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18808.x · Cited by 164
Toxicology of antisense therapeutics
Jason, T. L. H., Koropatnick, J. D., & Berg, R. W. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.017 · Cited by 161
Krug, A., Veeraswamy, R., Pekosz, A., Kanagawa, O., Unanue, E. R., Colonna, M., & Cella, M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021091 · Cited by 160
Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P. W., Fisher, D. C., Nadler, L. M., Coffman, R. L., & Freedman, A. S. (2004) · Blood · doi:10.1182/blood-2004-06-2156 · Cited by 154
Link, B. K., Ballas, Z. K., Weisdorf, D. J., Wooldridge, J. E., Bossler, A., Shannon, M., Rasmussen, W. L., Krieg, A. Μ., & Weiner, G. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211304.60126.8f · Cited by 153
Self-citationMason, K. A., Ariga, H., Neal, R. E., Valdecanas, D. R., Hunter, N. R., Krieg, A. Μ., Whisnant, J. K., & Milas, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.361.11.1 · Cited by 153
Self-citationSchlecht‐Louf, G., Garcia, S., Escriou, N., Freitas, A. A., Leclerc, C., & Dadaglio, G. (2004) · Blood · doi:10.1182/blood-2004-02-0426 · Cited by 152
Appay, V., Jandus, C., Voelter, V., Reynard, S., Coupland, S. E., Rimoldi, D., Líénard, D., Guillaume, P., Krieg, A. Μ., Cerottini, J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1670 · Cited by 152
Self-citationCpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide
Miconnet, I., Koenig, S., Speiser, D. E., Krieg, A. Μ., Guillaume, P., Cerottini, J., & Romero, P. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1212 · Cited by 147
Self-citationVollmer, J., Weeratna, R. D., Jurk, M., Samulowitz, U., McCluskie, M. J., Payette, P., Davis, H. L., Schetter, C., & Krieg, A. Μ. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01962.x · Cited by 146
Self-citationToka, F. N., Suvas, S., & Rouse, B. T. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13082-13089.2004 · Cited by 144
Dávila, E., & Celis, E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.539 · Cited by 141
Ishii, K. J., Takeshita, F., Gürsel, İ., Gürsel, M., Conover, J., Nussenzweig, A., & Klinman, D. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020773 · Cited by 139
Weigel, B. J., Rodeberg, D. A., Krieg, A. Μ., & Blazar, B. R. (2003) · PubMed · Cited by 133
Self-citationKim, S. K., Ragupathi, G., Musselli, C., Choi, S.-J., Park, Y. S., & Livingston, P. O. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00316-3 · Cited by 128
Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides.
Baines, J., & Celis, E. (2003) · PubMed · Cited by 122
B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides
Jahrsdörfer, B., Mühlenhoff, L., Blackwell, S. E., Wagner, M., Poeck, H., Hartmann, E., Jox, R. J., Giese, T., Emmerich, B., Endres, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1890 · Cited by 121
Heckelsmiller, K., Beck, S., Rall, K., Sipos, B., Schlamp, A., Tuma, E., Rothenfußer, S., Endres, S., & Hartmann, G. (2002) · European Journal of Immunology · Cited by 117
Rothenfußer, S., Hornung, V., Ayyoub, M., Britsch, S., Towarowski, A., Krug, A., Sarris, A., Lübenow, N., Speiser, D. E., Endres, S., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1091 · Cited by 116
Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity
Lonsdorf, A. S., Kuekrek, H., Stern, B. V., Boehm, B. O., Lehmann, P., & Tary‐Lehmann, M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.3941 · Cited by 112
In vivo manipulation of dendritic cells to induce therapeutic immunity
Mérad, M., Sugie, T., Engleman, E. G., & Fong, L. H. (2002) · Blood · doi:10.1182/blood.v99.5.1676 · Cited by 108
Siegrist, C., Pihlgren, M., Tougne, C., Efler, S. M., Morris, M. L., Al-Adhami, M., Cameron, D. W., Cooper, C., Heathcote, J., Davis, H. L., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.014 · Cited by 108
Sandler, A. D., Chihara, H., Kobayashi, G., Zhu, X., Miller, M. A., Scott, D. L., & Krieg, A. Μ. (2003) · PubMed · Cited by 106
Self-citationJahrsdörfer, B., Wooldridge, J. E., Blackwell, S. E., Taylor, C. M., Griffith, T. S., Link, B. K., & Weiner, G. J. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0604373 · Cited by 103
Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment
Carson, W. E., Shapiro, C. L., Crespin, T. R., Thornton, L. M., & Andersen, B. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1016-03 · Cited by 94
Eralp, Y., Wang, X., Wang, J., Maughan, M. F., Polo, J. M., & Lachman, L. B. (2004) · Breast Cancer Research · doi:10.1186/bcr787 · Cited by 93
Damiano, V., Caputo, R., Bianco, R., D'Armiento, F. P., Leonardi, A., De Placido, S., Bianco, A. R., Agrawal, S., Ciardiello, F., & Tortora, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1943 · Cited by 90
Buhtoiarov, I. N., Lum, H. D., Berke, G., Sondel, P. M., & Rakhmilevich, A. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.309 · Cited by 88
Kim, T., Myoung, H.-J., Kim, J., Moon, I. S., Kim, T., Ahn, W., & Sin, J. (2002) · PubMed · Cited by 83
Ghoreishi, M., & Dutz, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2635 · Cited by 83
APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells
Warren, T. L., Bhatia, S. K., Acosta, A. M., Dahle, C. E., Ratliff, T. L., Krieg, A. Μ., & Weiner, G. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6244 · Cited by 82
Self-citationChaudhry, U. I., Kingham, T. P., Plitas, G., Katz, S. C., Raab, J. R., & DeMatteo, R. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1908 · Cited by 81
Enhancement of Infectious Disease Vaccines Through TLR9-Dependent Recognition of CpG DNA
McCluskie, M. J., & KRIEG, A. M. (2006) · Springer eBooks · doi:10.1007/3-540-32636-7_6 · Cited by 79
Self-citationPhase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Witt, P. L., Ritch, P. S., Reding, D. J., et al. (1993) · PubMed · Cited by 73
Líénard, D., Rimoldi, D., Marchand, M., Dietrich, P., van Baren, N., Geldhof, C., Batard, P., Guillaume, P., Ayyoub, M., Pittet, M. J., et al. (2004) · PubMed · Cited by 72
Dercamp, C., Chemin, K., Caux, C., Trinchieri, G., & Vicari, A. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1319 · Cited by 70
Chu, Y., Wang, L.-X., Yang, G., Ross, H. J., Urba, W. J., Prell, R. A., Jooss, K. U., Xiong, S., & Hu, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199198.43587.ba · Cited by 69
Pratesi, G., Petrangolini, G., Tortoreto, M., Addis, A., Belluco, S., Rossini, A., Selleri, S., Rumio, C., Ménard, S., & Balsari, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0602 · Cited by 66
Wang, H., Rayburn, E. R., Wang, W., Kandimalla, E. R., Agrawal, S., & Zhang, R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0094 · Cited by 59
Balsari, A., Tortoreto, M., Besusso, D., Petrangolini, G., Sfondrini, L., Maggi, R., Ménard, S., & Pratesi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.023 · Cited by 56
Speiser, D. E., Pittet, M. J., Rimoldi, D., Guillaume, P., Luescher, I. F., Líénard, D., Lejeune, F. J., Cerottini, J., & Romero, P. J. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.010 · Cited by 55
Okano, F., Mérad, M., Furumoto, K., & Engleman, E. G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2645 · Cited by 46
Daftarian, P. M., Song, G.-Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., & Ellenhorn, J. D. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0169 · Cited by 46
Bourquin, C., Schreiber, S. C., Beck, S., Hartmann, G., & Endres, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21681 · Cited by 42
Ishii, K. J., Kawakami, K., Gürsel, İ., Conover, J., Joshi, B. H., Klinman, D. M., & Puri, R. K. (2003) · PubMed · Cited by 37
der Most, R. G. V., Himbeck, R. P., Aarons, S. J., Carter, S. J., Larma, I., Robinson, C., Currie, A. J., & Lake, R. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000187958.38179.a9 · Cited by 29
Ohashi, K., Kobayashi, G., Fang, S. H., Zhu, X., Antonia, S. J., Krieg, A. Μ., & Sandler, A. D. (2006) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2006.04.034 · Cited by 26
Self-citationA 'good death' for tumor immunology
Storkus, W. J., & Falo, L. D. (2007) · Nature Medicine · doi:10.1038/nm0107-28 · Cited by 24
Thompson, J. A., Kuzel, T. M., Bukowski, R., Masciari, F., & Schmalbach, T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.4644 · Cited by 24
Kim, Y. H., Girardi, M., McAuley, S., & Schmalbach, T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.6600 · Cited by 23
Augmenting the Potency of Breast Cancer Vaccines: Combined Modality Immunotherapy
Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2004) · Breast Disease · doi:10.3233/bd-2004-20103 · Cited by 20
Cited by
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Intestinal Bacteria and the Regulation of Immune Cell Homeostasis
Hill, D. A., & Artis, D. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101330 · Cited by 586
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Infection-mimicking materials to program dendritic cells in situ
Ali, O. A., Huebsch, N., Cao, L., Dranoff, G., & Mooney, D. J. (2009) · Nature Materials · doi:10.1038/nmat2357 · Cited by 434
Metadata
- Authors
- Krieg, A. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-05-01
- Volume
- 117
- Issue
- 5
- Pages
- 1184-1194
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2117684163
- Cited by
- 429
- References
- 118
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.